Clinical characteristics and outcomes in critical patients with hemorrhagic fever with renal syndrome

BMC Infectious Diseases

Xue-Fan Bai³  Jun-Ning Wang³  Ye Zhang³  Wei Jiang³  Hai-Tao Yu³  Huan Li²  Lu Bai¹  Jing Li³  Ping-Zhong Wang³  Hong Du³ 

[1] Center for Clinical Laboratory, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi, China;Center for Clinical Laboratory, Tangdu Hospital, Fourth Military Medical University, Xi’an, Shaanxi, China;Center for Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, 569 Xinsi Rd, Baqiao District, Xi’an, Shaanxi 710038, China

关键词: Hantavirus;    Prognosis;    Hemorrhagic fever with renal syndrome;   

Others  :  1134174
DOI  :  10.1186/1471-2334-14-191

 received in 2014-01-06, accepted in 2014-03-31,  发布年份 2014

【 摘 要 】

Background

Hemorrhagic fever with renal syndrome (HFRS) has become an important public health concern because of the high incidence and mortality rates, and limited treatment and vaccination. Until now, clinical studies on characteristics and outcomes in critical patients with HFRS have been limited. The aim of this study was to observe the clinical characteristics and cumulative proportions surviving and explore the predictive effects and risk factors for prognosis.

Methods

A detailed retrospective analysis of clinical records for critical HFRS patients was conducted. The patients enrolled were treated in the centre for infectious diseases, Tangdu Hospital, between January 2008 and August 2012. The clinical characteristics between the survivors and non-survivors were compared by Student’s t-test or Chi-square test. The risk clinical factors for prognosis were explored by logistic regression analysis. The predictive effects of prognosis in clinical and laboratory parameters were analyzed by receiver operating characteristic (ROC) curves. The cumulative proportions surviving at certain intervals in the critical patients were observed by Kaplan-Meier survival analysis.

Results

Of the 75 patients enrolled, the cumulative proportion surviving was 70.7% at the second week interval, with a 28-day mortality rate of 36.3%. The non-survivors tended to have higher frequencies of agitation, dyspnea, conjunctival hemorrhage, coma, cardiac failure, acute respiratory distress syndrome (ARDS) and encephalopathy (P < .05). ARDS, conjunctival hemorrhage and coma were risk factors for death in the critical patients with HFRS. The non-survivors were found to have lower serum creatinine (Scr) levels (P < .001) and higher incidences of prolonged prothrombin time (PT) (P = .006), activated partial thromboplastin time (APTT) (P = .003) and elevated white blood cells (WBC) levels (P = .005), and the laboratory parameters mentioned above reached statistical significance for predicting prognosis (P < .05).

Conclusion

The high fatality in critical patients with HFRS underscores the importance of clinicians’ alertness to the occurrence of potentially fatal complications and changes in biochemical status to ensure that timely and systematically supportive treatment can be initiated when necessary.

【 授权许可】

   
2014 Du et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Schmaljohn CS, Hasty SE, Dalrymple JM, LeDuc JW, Lee HW, von Bonsdorff CH, Brummer-Korvenkontio M, Vaheri A, Tsai TF, Regnery HL, Goldgaber D, Lee PW: Antigenic and genetic properties of viruses linked to hemorrhagic fever with renal syndrome. Science 1985, 227(4690):1041-1044.
• [2]Muranyi W, Bahr U, Zeier M, van der Woude FJ: Hantavirus infection. J Am Soc Nephrol 2005, 16(12):3669-3679.
• [3]Schmaljohn C, Hjelle B: Hantaviruses: a global disease problem. Emerg Infect Dis 1997, 3(2):95-104.
• [4]Song G: Manual for Prevention and Cure of Hemorrhagic Fever with Renal Syndrome. Beijing: People’s Health Press; 1998.
• [5]Luo CW, Chen HX: Epidemiological characteristics and the strategy of vaccination on hemorrhagic fever with renal syndrome in the last 10 years, in China. Zhonghua Liu Xing Bing Xue Za Zhi 2008, 29(10):1017-1019.
• [6]Ma C, Yu P, Nawaz M, Zuo S, Jin T, Li Y, Li J, Li H, Xu J: Hantaviruses in rodents and humans, Xi'an. PR China. J Gen Virol 2012, 93(Pt 10):2227-2236.
• [7]Liu YX, Feng D, Zhang Q, Jia N, Zhao ZT, De Vlas SJ, Li J, Zhang PH, Yang H, Min JS, Feng PT, Ma SB, Cao WC: Key differentiating features between scrub typhus and hemorrhagic fever with renal syndrome in northern China. Am J Trop Med Hyg 2007, 76(5):801-805.
• [8]Rigau-Perez JG, Clark GG, Gubler DJ, Reiter P, Sanders EJ, Vorndam AV: Dengue and dengue hemorrhagic fever. Lancet 1998, 352(9132):971-977.
• [9]Gregson A, Edelman R: Dengue virus infection. Pediatr Infect Dis J 2003, 22(2):179-181.
• [10]Welzel TM, Zeier M, Darai G, Ritz E: Hantavirus infection–new threats by an old virus. Nephrol Dial Transplant 1998, 13(11):2731-2733.
• [11]Lee JS: Clinical features of hemorrhagic fever with renal syndrome in Korea. Kidney Int Suppl 1991, 35:S88-93.
• [12]Bruno P, Hassell LH, Brown J, Tanner W, Lau A: The protean manifestations of hemorrhagic fever with renal syndrome: a retrospective review of 26 cases from Korea. Ann Intern Med 1990, 113(5):385-391.
• [13]Gavrilovskaya IN, Brown EJ, Ginsberg MH, Mackow ER: Cellular entry of hantaviruses which cause hemorrhagic fever with renal syndrome is mediated by β3 integrins. J Virol 1999, 73(5):3951-3959.
• [14]Hayasaka D, Maeda K, Ennis FA, Terajima M: Increased permeability of human endothelial cell line EA.hy926 induced by hantavirus-specific cytotoxic T lymphocytes. Virus Res 2007, 123(2):120-127.
• [15]Bai XF, Xu ZK: Hemorrhagic Fever with Renal Syndrome. Beijing: People’s Medical Publishing House; 2013.
• [16]Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A: Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Critical Care 2007, 11(2):R31. BioMed Central Full Text
• [17]Chinese Medical Association to severe medicine branch: Guidelines for the Diagnosis and Treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome (2006). 2011. http://www.csccm.org/cn/news.asp?id=115.html webcite
• [18]Chen WC: Possible interventional therapies in severe sepsis or septic shock. Acta Anaesthesiol Taiwan 2012, 50(2):74-77.
• [19]Liu DV: Practical Critical Care Medicine. Beijing: People’s Medical Publishing House; 2010.
• [20]Hochstadt A, Meroz Y, Landesberg G: Myocardial dysfunction in severe sepsis and septic shock: more questions than answers? J Cardiothorac Vasc Anesth 2011, 25(3):526-535.
• [21]Plyusnin A, Morzunov SP: Virus evolution and genetic diversity of hantaviruses and their rodent hosts. Curr Top Microbiol Immunol 2001, 256:47-75.
• [22]Ghahramani N, Shadrou S, Hollenbeak C: A systematic review of continuous renal replacement therapy and intermittent haemodialysis in management of patients with acute renal failure. Nephrology (Carlton) 2008, 13(7):570-578.
• [23]Swartz RD, Bustami RT, Daley JM, Gillespie BW, Port FK: Estimating the impact of renal replacement therapy choice on outcome in severe acute renal failure. Clin Nephrol 2005, 63(5):335-345.
• [24]Kim S, Sung SH, An HR, Jun YH, Yu M, Ryu DR, Kim SJ, Kang DH, Choi KB: A case report of crescentic glomerulonephritis associated with hantaan virus infection. Nephrol Dial Transplant 2010, 25(8):2790-2792.
• [25]Parkash O, Almas A, Jafri SM, Hamid S, Akhtar J, Alishah H: Severity of acute hepatitis and its outcome in patients with dengue fever in a tertiary care hospital Karachi, Pakistan (South Asia). BMC Gastroenterol 2010, 10:43. BioMed Central Full Text
• [26]Levi M, Löwenberg EC: Thrombocytopenia in critically ill patients. Semin Thromb Hemost 2008, 34(5):417-424.
• [27]Rasche FM, Uhel B, Kruger DH, Karges W, Czock D, Hampl W, Keller F, Meisel H, von Muller L: Thrombocytopenia and acute renal failure in Puumala hantavirus infections. Emerg Infect Dis 2004, 10(8):1420-1425.
• [28]Vanderschueren S, De Weerdt A, Malbrain M, Vankersschaever D, Frans E, Wilmer A, Bobbaers H: Thrombocytopenia and prognosis in intensive care. Crit Care Med 2000, 28(6):1871-1876.
• [29]Guzman MG, Kouri G: Dengue: an update. Lancet Infect Dis 2002, 2(1):33-42.
• [30]Huang YH, Liu CC, Wang ST, Lei HY, Liu HL, Lin YS, Wu HL, Yeh TM: Activation of coagulation and fibrinolysis during dengue virus infection. J Med Virol 2001, 63(3):247-251.
• [31]Chua MN, Molanida R, de Guzman M, Laberiza F: Prothrombin time and partial thromboplastin time as a predictor of bleeding in patients with dengue hemorrhagic fever. Southeast Asian J Trop Med Public Health 1993, 24(Suppl 1):141-143.
• [32]Lee IK, Liu JW, Yang KD: Clinical characteristics, risk factors, and outcomes in adults experiencing dengue hemorrhagic fever complicated with acute renal failure. Am J Trop Med Hyg 2009, 80(4):651-655.